●Core Identity: IGF-DES is a truncated analog of the naturally occurring hormone Insulin-like Growth Factor-1 (IGF-1). Specifically, it lacks the first three amino acids (N-terminal tripeptide: Glycine-Proline-Glutamate) found in the full-length IGF-1 molecule. This modification is not naturally occurring in humans.
●Origin: It arises from research exploring the structure-activity relationships of IGF-1. Scientists discovered that removing these first three amino acids significantly altered the peptide's interaction with its binding proteins.
●Key Distinction from IGF-1: Full-length IGF-1 circulates in the blood predominantly bound (over 99%) to a family of IGF Binding Proteins (IGFBPs). This binding stabilizes IGF-1 but also severely restricts its bioavailability and potency at the tissue level, acting as a reservoir and regulatory mechanism.
●The "DES" Advantage (Theoretical): The deletion of the first three amino acids drastically reduces IGF-DES's affinity for most IGFBPs, particularly IGFBP-3, the major carrier. This theoretically results in:
○Greatly Increased Free Fraction: A much higher percentage of IGF-DES circulates in the biologically active, unbound ("free") state compared to IGF-1.
○Enhanced Bioactivity: This increased free fraction is believed to translate to significantly greater receptor activation potency at target tissues (like muscle and cartilage) on a molar basis compared to IGF-1. Studies suggest it could be 10-100 times more potent in vitro and in some animal models.
